CSF and Brain Structural Imaging Markers of the Alzheimer's Pathological Cascade

被引:32
|
作者
Yang, Xianfeng [1 ]
Tan, Ming Zhen [1 ]
Qiu, Anqi [1 ,2 ,3 ]
机构
[1] Natl Univ Singapore, Dept Bioengn, Singapore 117548, Singapore
[2] Natl Univ Singapore, Clin Imaging Res Ctr, Singapore 117548, Singapore
[3] Singapore Inst Clin Sci, Agcy Sci Technol & Res, Singapore, Singapore
来源
PLOS ONE | 2012年 / 7卷 / 12期
基金
英国医学研究理事会;
关键词
MILD COGNITIVE IMPAIRMENT; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; HIPPOCAMPAL ATROPHY; DISEASE; MRI; RECOMMENDATIONS; BIOMARKERS; DEMENTIA;
D O I
10.1371/journal.pone.0047406
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Cerebral spinal fluid (CSF) and structural imaging markers are suggested as biomarkers amended to existing diagnostic criteria of mild cognitive impairment (MCI) and Alzheimer's disease (AD). But there is no clear instruction on which markers should be used at which stage of dementia. This study aimed to first investigate associations of the CSF markers as well as volumes and shapes of the hippocampus and lateral ventricles with MCI and AD at the baseline and secondly apply these baseline markers to predict MCI conversion in a two-year time using the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Our results suggested that the CSF markers, including A beta 42, t-tau, and p-tau, distinguished MCI or AD from NC, while the A beta 42 CSF marker contributed to the differentiation between MCI and AD. The hippocampal shapes performed better than the hippocampal volumes in classifying NC and MCI, NC and AD, as well as MCI and AD. Interestingly, the ventricular volumes were better than the ventricular shapes to distinguish MCI or AD from NC, while the ventricular shapes showed better accuracy than the ventricular volumes in classifying MCI and AD. As the CSF markers and the structural markers are complementary, the combination of them showed great improvements in the classification accuracies of MCI and AD. Moreover, the combination of these markers showed high sensitivity but low specificity for predicting conversion from MCI to AD in two years. Hence, it is feasible to employ a cross-sectional sample to investigate dynamic associations of the CSF and imaging markers with MCI and AD and to predict future MCI conversion. In particular, the volumetric information may be good for the early stage of AD, while morphological shapes should be considered as markers in the prediction of MCI conversion to AD together with the CSF markers.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] In the era of FDG PET, is it time for brain perfusion SPECT to gain a place in Alzheimer's disease imaging biomarkers?
    Valotassiou, Varvara
    Angelidis, George
    Psimadas, Dimitrios
    Tsougos, Ioannis
    Georgoulias, Panagiotis
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (04) : 969 - 971
  • [22] Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer's pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform
    Martinez-Dubarbie, Francisco
    Guerra-Ruiz, Armando
    Lopez-Garcia, Sara
    Lage, Carmen
    Fernandez-Matarrubia, Marta
    Infante, Jon
    Pozueta-Cantudo, Ana
    Garcia-Martinez, Maria
    Corrales-Pardo, Andrea
    Bravo, Maria
    Lopez-Hoyos, Marcos
    Irure-Ventura, Juan
    Sanchez-Juan, Pascual
    Garcia-Unzueta, Maria Teresa
    Rodriguez-Rodriguez, Eloy
    ALZHEIMERS RESEARCH & THERAPY, 2023, 15 (01)
  • [23] CSF Ubiquitin As a Specific Biomarker in Alzheimer's Disease
    Kandimalla, Ramesh J.
    Anand, R.
    Veeramanikandan, R.
    Wani, Willayat Yousuf
    Prabhakar, Sudesh
    Grover, Vinod K.
    Bharadwaj, Neerja
    Jain, Kajal
    Gill, Kiran Dip
    CURRENT ALZHEIMER RESEARCH, 2014, 11 (04) : 340 - 348
  • [24] Increased CSF-decorin predicts brain pathological changes driven by Alzheimer's Aβ amyloidosis
    Jiang, Richeng
    Smailovic, Una
    Haytural, Hazal
    Tijms, Betty M.
    Li, Hao
    Haret, Robert Mihai
    Shevchenko, Ganna
    Chen, Gefei
    Abelein, Axel
    Gobom, Johan
    Frykman, Susanne
    Sekiguchi, Misaki
    Fujioka, Ryo
    Watamura, Naoto
    Sasaguri, Hiroki
    Nystrom, Sofie
    Hammarstrom, Per
    Saido, Takaomi C.
    Jelic, Vesna
    Syvanen, Stina
    Zetterberg, Henrik
    Winblad, Bengt
    Bergquist, Jonas
    Visser, Pieter Jelle
    Nilsson, Per
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2022, 10 (01)
  • [25] Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach
    Begcevic, Ilijana
    Brinc, Davor
    Brown, Marshall
    Martinez-Morillo, Eduardo
    Goldhardt, Oliver
    Grimmer, Timo
    Magdolen, Viktor
    Batruch, Ihor
    Diamandis, Eleftherios P.
    JOURNAL OF PROTEOMICS, 2018, 182 : 12 - 20
  • [26] Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease
    Ramusino, Matteo Cotta
    Garibotto, Valentina
    Bacchin, Ruggero
    Altomare, Daniele
    Dodich, Alessandra
    Assal, Frederic
    Mendes, Aline
    Costa, Alfredo
    Tinazzi, Michele
    Morbelli, Silvia D.
    Bauckneht, Matteo
    Picco, Agnese
    Dottorini, Massimo E.
    Tranfaglia, Cristina
    Farotti, Lucia
    Salvadori, Nicola
    Moretti, Davide
    Savelli, Giordano
    Tarallo, Anna
    Nobili, Flavio
    Parapini, Maura
    Cavaliere, Carlo
    Salvatore, Elena
    Salvatore, Marco
    Boccardi, Marina
    Frisoni, Giovanni B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (02) : 270 - 280
  • [27] Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease
    Morenas-Rodriguez, Estrella
    Alcolea, Daniel
    Suarez-Calvet, Marc
    Munoz-Llahuna, Laia
    Vilaplana, Eduard
    Sala, Isabel
    Subirana, Andrea
    Querol-Vilaseca, Marta
    Carmona-Iragui, Maria
    Illan-Gala, Ignacio
    Ribosa-Nogue, Roser
    Blesa, Rafael
    Haass, Christian
    Fortea, Juan
    Lleo, Alberto
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [28] CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease
    Teuber-Hanselmann, Sarah
    Rekowski, Jan
    Vogelgsang, Jonathan
    von Arnim, Christine
    Reetz, Kathrin
    Stang, Andreas
    Joeckel, Karl-Heinz
    Wiltfang, Jens
    Esselmann, Herrmann
    Otto, Markus
    Tumani, Hayrettin
    Herring, Arne
    Keyvani, Kathy
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2020, 91 (01) : 40 - 48
  • [29] CSF tau markers are correlated with hippocampal volume in Alzheimer's disease
    de Souza, Leonardo C.
    Chupin, Marie
    Lamari, Foudil
    Jardel, Claude
    Leclercq, Delphine
    Colliot, Olivier
    Lehericy, Stephane
    Dubois, Bruno
    Sarazin, Marie
    NEUROBIOLOGY OF AGING, 2012, 33 (07) : 1253 - 1257
  • [30] Disrupted structural and functional brain connectomes in mild cognitive impairment and Alzheimer's disease
    Dai, Zhengjia
    He, Yong
    NEUROSCIENCE BULLETIN, 2014, 30 (02) : 217 - 232